Association between clozapine-induced hypertriglyceridemia and defenestration of liver sinusoidal endothelial cells
Open Access
- 6 August 2026
- journal article
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Abstract
Clozapine is the most effective antipsychotic drug, while also causing the most severe metabolic side effects. The underlying mechanisms of these side effects appear multifactorial and are not entirely understood. We hypothesized that liver sinusoidal endothelial cells (LSEC) dysfunction is linked to the metabolic side effects of clozapine, based on known association between reduced LSEC porosity, hypertriglyceridemia and insulin resistance. Accordingly, we conducted a translational study by assessing the porosity of murine LSECs following clozapine exposure in vitro and correlating serum clozapine concentrations with metabolic parameters in routine human blood samples. The patient data showed a correlation for clozapine serum concentrations with both triglycerides (Spearman’s ρ = 0.47, P = 0.00024) and glucose levels (ρ = 0.24, P = 0.034), but no correlation with LDL cholesterol (ρ = −0.04, P = 0.82) or HDL cholesterol (ρ = −0.22, P = 0.088). The in vitro experiments showed a concentration-dependent reduction in murine LSEC porosity (P for trend = 0.00036). Together, these findings support a link between clozapine exposure and reduced LSEC porosity. This represents a promising point of intervention that potentially could expand safe access to clozapine as a highly effective antipsychotic treatment for a broader population, also in individuals at high risk for metabolic and cardiovascular side effects.Keywords
This publication has 45 references indexed in Scilit:
- Misuse of the Well-Stirred Model of Hepatic Drug ClearanceDrug Metabolism and Disposition, 2007
- Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medicationSchizophrenia Research, 2006
- Age‐related changes in the hepatic sinusoidal endothelium impede lipoprotein transfer in the rat†Hepatology, 2005
- Diagnosis and Management of the Metabolic SyndromeCirculation, 2005
- Estimating regression models with unknown break‐pointsStatistics in Medicine, 2003
- Comparability of whole‐blood and plasma clozapine and norclozapine concentrationsBritish Journal of Clinical Pharmacology, 2003
- The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate inapob-lipoprotein-depleted plasma (FERHDL)Clinical Biochemistry, 2001
- Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearanceBritish Journal of Clinical Pharmacology, 1998
- Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood methodBritish Journal of Clinical Pharmacology, 1997
- Lipoproteins and the liver sieve: The role of the fenestrated sinusoidal endothelium in lipoprotein metabolism, atherosclerosis, and cirrhosisHepatology, 1995